EV-035: 2-pyridone-based topoisomerase inhibitors

Evolva

A presentation on EV-035 at the Superbugs and Superdrugs conference in 2012

Evolva

  • Topped our upper estimate! Evolva raises CHF 86M ($86M). Cash position now > CHF 100M ($100M). https://t.co/aiPI46jsTK

Sign up to receive our
Press Releases!

Sign up